Comparison of the effectiveness of first- and second-line canakinumab therapy in pediatric colchicine-resistant familial Mediterranean fever: a real-world study
Background Comparative data on first-line versus second-line canakinumab following anakinra in pediatric colchicine-resistant familial Mediterranean fever (crFMF) are lacking. We compared effectiveness, flare characteristics, and flare-free survival between treatment sequences.Research design and methods This retrospective single-center cohort study included 89 pediatric patients with crFMF carrying biallelic pathogenic exon 10 Mediterranean Fever gene (MEFV) variants who received canakinumab for at least 6 months, either as first-line therapy (n = 48) or following anakinra (n = 41).Results Canakinumab significantly reduced median Pras Disease Severity Score from 8 to 6 and International Severity Scoring System for familial Mediterranean fever from 4 to 1 (both p < 0.001). Patients receiving first-line canakinumab had fewer attacks during the first 6 months (p = 0.014), lower early flare rates (2.1% vs 17.1%; p = 0.022), and a longer time to first flare (14 vs 10 months; p = 0.030) than those receiving second-line treatment. Flare-free survival tended to favor first-line treatment (35 vs 19 months; log-rank p = 0.087), while overall flare rates were similar. Most first flares occurred during dose-interval extension, particularly at 8 weeks.Conclusions Canakinumab provided effective disease control regardless of treatment sequence. However, patients receiving first-line canakinumab experienced fewer early flares and a longer time to first flare compared with those receiving second-line treatment.
Authors
- Betül Sözeri (ORCID: https://orcid.org/0000-0002-5079-5644)
- Sıla Atamyıldız Uçar (ORCID: https://orcid.org/0000-0002-4283-0921)
- Eray Tunce (ORCID: https://orcid.org/0000-0002-4801-6605)
- Neslihan Kara Çanlıoğlu
Institutions
- Sağlık Bilimleri Üniversitesi (TR)
Publication Details
- Journal
- Expert Opinion on Biological Therapy
- Published
- 2026-11-14
- DOI
- https://doi.org/10.1080/14712598.2026.2763307
- Primary Topic
- Inflammasome and immune disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00